Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model

Surgery (United States)

Volumn 152, Issue 6, 2012, Pages 1068-1077

  Quinn, Thomas J ^a   Yuan, Ziqiang ^a   Adem, Asha ^a   Geha, Rula ^a   Vrikshajanani, Chakravarthy ^a   Koba, Wade ^a   Fine, Eugene ^a   Hughes, David T ^a   Schmid, Herbert A ^b   Libutti, Steven K ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PASIREOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; COLORIMETRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HISTOLOGY; INSULIN BLOOD LEVEL; INSULINOMA; KNOCKOUT MOUSE; MOUSE; MULTIPLE ENDOCRINE NEOPLASIA; NICK END LABELING; NONHUMAN; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; INSULIN; MICE; MICE, KNOCKOUT; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; SOMATOSTATIN;

EID: 84869496395     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.08.021     Document Type: Article

References (22)

1. Key C. Cancer of the pancreas. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, editors. SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988-2001, patient and tumor characteristics. Bethesda, MD: National Cancer Institute, SEER Program; 2007. NIH Pub. No. 07-6215.
2. W. Kimura, A. Kuroda, and Y. Morioka Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases Dig Dis Sci 36 1991 933 942
3. J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, and J.E. Mares One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 2008 3063 3072
4. F. Ehehalt, H. Saeger, C. Schmidt, and R. Grützmann Neuroendocrine tumors of the pancreas Oncologist 12 2009 456 467
5. W.W. de Herder, B. Niederle, J.Y. Scoazec, S. Pauwels, G. Kloppel, and M. Falconi Frascati Consensus Conference; European Neuroendocrine Tumor Society. Well-differentiated pancreatic tumor/carcinoma: insulinoma Neuroendocrinology 84 2006 183 188
6. N.C. Sturgess, R.Z. Kozlowski, C.A. Carrington, C.N. Hales, and M.L. Ashford Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin secreting cell line Br J Pharmacol 95 1988 83 94
7. R.R. Perry, and A.I. Vinik Clinical review 72: diagnosis and management of functioning islet cell tumors J Clin Endocrinol Metab 80 1995 2273 2278
8. P.N. Goode, J.R. Farndon, J. Anderson, I.D. Johnston, and J.A. Morte Diazoxide in the management of patients with insulinoma World J Surg 10 1986 586 592
9. G.V. Gill, O. Rauf, and I.A. MacFarlane Diazoxide treatment for insulinoma: a national UK survey Postgrad Med J 73 1997 640 641
10. M. Usukura, T. Yoneda, N. Oda, Y. Yamamoto, H. Takata, and K. Hasatani Medical treatment of benign insulinoma using octreotide LAR: a case report Endocr J 54 2007 95 101
11. J. Bertherat, F. Tenenbaum, K. Perlemoine, C. Videau, J.L. Alberini, and B. Richard Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study J Clin Endocrinol Metab 88 2003 5353 5360
12. W. Bauer, U. Briner, W. Doepfner, R. Haller, R. Huguenin, and P. Marbach SMS 201-995: a very potent and selective octapeptide analog of somatostatin with prolonged action Life Sci 31 1982 1133 1140
13. M. Pawlikowski, and G. Melen-Mucha Somatostatin analogs - from new molecules to new applications Curr Opin Pharmacol 4 2004 608 613
14. M. Fedele, I. De Martino, R. Pivonello, A. Ciarmiello, M.L. Del Basso De Caro, and R. Visone SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas Clin Cancer Res 13 2007 2738 2744
15. J. van der Hoek, W.W. de Herder, R.A. Feelders, A.J. van der Lely, P. Uitterlinden, and V. Boerlin A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients J Clin Endocrinol Metab 89 2004 638 645
16. S. Petersenn, J. Schopohl, A. Barkan, P. Mohideen, A. Colao, and R. Abs Pasireotide Acromegaly Study Group. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial J Clin Endocrinol Metab 95 2010 2781 2789
17. A.C. Powell, and S.K. Libutti Multiple endocrine neoplasia type 1: clinical manifestations and management Cancer Treat Res 153 2010 287 302
18. Y. Jiao, C. Shi, B.H. Edil, R.F. de Wilde, D.S. Klimstra, and A. Maitra DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 2011 1199 1203
19. H.C. Shen, M. He, A. Powell, A. Adem, D. Lorang, and C. Heller Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1 Cancer Res 69 2009 1858 1866
20. S.L. Asa Pancreatic endocrine tumors Mod Pathol 24 Suppl 2 2011 S66 S77
21. S.V. de Sá, M.L. Corrêa-Giannella, M.C. Machado, J.J. de Souza, M.A. Pereira, and R.A. Patzina Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas Endocr Relat Cancer 13 2006 69 78
22. D.L. Kleinberg, P. Ameri, and B. Singh Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia Pituitary 14 2011 44 52